App-Quantinova.ai

Long-Term Outcome of Low Dose of Anti-t-Lymphocyte Globulin in the Prophylaxis of Graft-Versus-Host Disease in Unrelated Myeloablative Hematopoietic Stem Cell Transplantation

Juan Manuel Cerezo - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Graft-versus-host disease

EZ-2053

MO-TRANS: A Phase 2b Placebo-Controlled Study of Mocravimod As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplant

Marcos De Lima - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute promyelocytic leukemia

Cyclosporine A

The Impact of Pre-Transplant Extramedullary Disease on the Outcome of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Children- on Behalf of PDWP/EBMT

Juliana Silva - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Allopurinol

Idiopathic Multicentric Castleman Disease Interactive Disease Awareness and Educational Tool for Pathologists

Elena Sabattini - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Castleman disease

N/A

Effectiveness of an Antifungal Stewardship Program in a Hematology Ward at a Madrid Teaching Hospital: The Time Is Now

Maria Arguello - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

amphotericin B

Enabling the Implementation of Next-Generation Sequencing into Clinical Diagnosis: Nemhesys Project

Jesus Maria Hernandez-Rivas - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hematology-oncology disease

N/A

Analysis of Patient Characteristics and Treatment Progression Patterns in R/R DLBCL Patients Prior to CAR T-Cell Therapy in EU4+UK Countries

Sari Heitner Enschede - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

Survival Analysis According to the Standardized Phase Angle Measured By Bioimpedanciometry to Estimate Body Composition in Patients with Hematological Malignancies during Nutritional Screening at Hospital Admission

Agustín María Hernández Sanchez - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hematological malignancies

N/A

Treatment Patterns and Outcomes in Lower-Risk, Non-Del(5q) Myelodysplastic Syndromes: Findings from a Global Real-World Medical Record Review Study

Maria Diez-Campelo - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelodysplastic Syndrome

N/A

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

Hun Ju Lee - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hodgkin's Lymphoma

brentuximab vedotin

Prospective Assessment of Motor Neurotoxicity and Sarcopenia in CD30+ Lymphoma Patients Treated with Brentuximab Vedotin. Single Center Multidisciplinary Unit Experience

Domingo Domenech Eva - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Peripheral Nervous System

Sarcopenia

brentuximab vedotin

Comparison of clinical severity scales for acute bronchiolitis in the emergency department

Elena Granda - Pediatric Academic Societies (PAS) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Does the PECARN rule for Traumatic Brain Injury in children under 2 years old work in Infants Younger than 3 Months?

JosÃ© Antonio Alonso Cadenas - Pediatric Academic Societies (PAS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Traumatic brain injury

N/A

Epidemiology of minor head trauma in infants younger than 3 months

JosÃ© Antonio Alonso Cadenas - Pediatric Academic Societies (PAS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Pediatric head trauma

N/A

Development of a research priorities agenda for a pediatric emergency medicine network.

Roberto Velasco - Pediatric Academic Societies (PAS) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Is an urine culture mandatory in all febrile neutropenic Pediatric patients with cancer?

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neutropenia

N/A

Mapping the PIK3CA-Related Overgrowth Spectrum (PROS) Patient and Caregiver Journey Using a Patient-Centered Approach

Dawn Aubel - Pediatric Academic Societies (PAS) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Phosphatidylinositol

Outcomes of late-onset Group B Streptococcus bacteremia in infants attended at the pediatric emergency department and risk factors for severe infection

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Septic shock

N/A

Predictors of invasive bacterial infection in febrile oncology patients attended in the Emergency Department

Borja Gomez - Pediatric Academic Societies (PAS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Secretory phospholipase A2 expression and activity in preterm clinical chorioamnionitis with fetal involvement

Daniele M. De Luca - Pediatric Academic Societies (PAS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Chorioamnionitis

Prostaglandin

Filters

24923 Abstracts